share_log

康希諾生物：海外監管公告

CANSINOBIO: Overseas Regulatory Notice

HKEX ·  Dec 4 05:31

Summary by Moomoo AI

康希諾生物股份公司於2024年12月4日公告，實際控制人之一毛慧華調整其H股持股方式。毛慧華將通過其控制的SCHELD Holding Limited持有的1,127,372股H股及11,387股H股，調整為通過Medicharms LLC及其個人分別持有。此次調整不影響公司實際控制人合計控制的股份數量和比例，亦不涉及市場減持或公司控制權變更。\\n毛慧華此次調整是出於資產規劃目的，Medicharms於2024年8月28日在美國Delaware成立，毛慧華為其唯一股東。調整後，毛慧華直接持有公司4,409,500股A股、4,797,328股H股，並間接通過CHAMPDEN和Medicharm...展開全部
康希諾生物股份公司於2024年12月4日公告，實際控制人之一毛慧華調整其H股持股方式。毛慧華將通過其控制的SCHELD Holding Limited持有的1,127,372股H股及11,387股H股，調整為通過Medicharms LLC及其個人分別持有。此次調整不影響公司實際控制人合計控制的股份數量和比例，亦不涉及市場減持或公司控制權變更。\\n毛慧華此次調整是出於資產規劃目的，Medicharms於2024年8月28日在美國Delaware成立，毛慧華為其唯一股東。調整後，毛慧華直接持有公司4,409,500股A股、4,797,328股H股，並間接通過CHAMPDEN和Medicharms持有6,000,000股H股和1,127,372股H股，合計持有公司6.6010%的股份。毛慧華的配偶巢守柏持股數未變。\\n此次持股方式調整後，毛慧華與公司控股股東宇學峰、朱濤、邱東旭於2024年12月3日簽署《一致行動協議》之補充協議，Medicharms承繼SCHELD在協議中的全部義務。四位實際控制人合計控制公司31.2944%的股份，未發生變化。
Cansinobio announced on December 4, 2024 that one of the actual controllers, Mao Huihua, adjusted her H shareholding method. Mao Huihua will adjust the 1,127,372 H shares and 11,387 H shares held by SCHELD Holding Limited, which she controls, to be held separately by Medicharms LLC and herself. This adjustment does not affect the total number and proportion of shares controlled by the actual controllers of the company, nor does it involve market share reduction or changes in corporate control. This adjustment by Mao Huihua is for asset planning purposes. Medicharms was established in Delaware, usa on August 28, 2024, with Mao Huihua as its sole shareholder. After the adjustment, Mao Huihua directly holds 4,409,500 A shares of the company, 4,797,328 H shares, and indirectly holds 6,000,000 H shares...Show More
Cansinobio announced on December 4, 2024 that one of the actual controllers, Mao Huihua, adjusted her H shareholding method. Mao Huihua will adjust the 1,127,372 H shares and 11,387 H shares held by SCHELD Holding Limited, which she controls, to be held separately by Medicharms LLC and herself. This adjustment does not affect the total number and proportion of shares controlled by the actual controllers of the company, nor does it involve market share reduction or changes in corporate control. This adjustment by Mao Huihua is for asset planning purposes. Medicharms was established in Delaware, usa on August 28, 2024, with Mao Huihua as its sole shareholder. After the adjustment, Mao Huihua directly holds 4,409,500 A shares of the company, 4,797,328 H shares, and indirectly holds 6,000,000 H shares and 1,127,372 H shares through CHAMPDEN and Medicharms, totaling 6.6010% of the company's shares. The shareholdings of Mao Huihua's spouse, Chao Shoubai, remain unchanged. After this adjustment in shareholding, Mao Huihua, along with the company's controlling shareholders Yu Xuefeng, Zhu Tao, and Qiu Dongxu, signed a supplementary agreement to the "Joint Action Agreement" on December 3, 2024, whereby Medicharms assumes all obligations of SCHELD in the agreement. The four actual controllers collectively control 31.2944% of the company's shares, with no changes made.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated